Related Experiment Video
Updated: Jul 23, 2025
11:15
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
Published on: September 1, 2018
8.0K
Immunotherapy for Recurrent Glioma-From Bench to Bedside
Yi Pu1,2, Guanyu Zhou2,3, Kejia Zhao2,3,4
1Laboratory of Mitochondria and Metabolism, Department of Burn and Reconstructive Surgery, West China Hospital, Sichuan University, Chengdu 610041, China.
Cancers
|July 14, 2023
Summary
Recurrent glioma, often resistant to standard treatments, shows promise with immunotherapy. Combining immune checkpoint blockade with other strategies like anti-angiogenesis antibodies enhances anti-tumor response.
Area of Science:
- Neuro-oncology
- Immunology
- Cancer Therapy
Background:
- Glioma is an aggressive brain tumor with high recurrence rates.
- Recurrent gliomas frequently develop resistance to chemotherapy and radiotherapy.
- Immunotherapy offers a promising avenue for treating recurrent glioma.
Purpose of the Study:
- To review current immunotherapies for recurrent glioma.
- To discuss the mechanisms of action for various immune strategies.
- To provide insights into novel therapeutic approaches based on recent preclinical and clinical data.
Main Methods:
- Review of preclinical models and clinical trials in recurrent glioma immunotherapy over the last 5 years.
- Analysis of combination strategies, including immune checkpoint blockade (ICB) and anti-angiogenesis antibodies.
- Exploration of oncolytic viruses, CAR-T therapies, and vaccination strategies.
Main Results:
- Immune checkpoint blockade (ICB) shows limited efficacy as monotherapy but is enhanced when combined with other immunotherapies, particularly anti-angiogenesis antibodies.
- Oncolytic viruses and CAR-T therapies demonstrate promising results in recurrent glioma.
- Vaccination strategies and immune-cell-based immunotherapies show potential in specific patient subgroups, with new antigenic targets identified.
Conclusions:
- Combination immunotherapies, especially ICB with anti-angiogenesis agents, enhance anti-tumor immune response in recurrent glioma.
- Oncolytic viruses, CAR-T, and vaccination strategies represent evolving therapeutic options.
- Further research into novel combination regimens is crucial for improving recurrent glioma treatment outcomes.
